Evidence map›Paper›PMID 41091513›Full record

ArticleJAMA dermatology2025

Skin Cancer Surveillance Program for Solid Organ Transplant Recipients.

David S Lee, Lusine Gigoyan, Ryan E Sells, Joshua R Nugent, Nelson B Goes, Hugh R Harris, Erna O Nishime, Gurpreet K Rihal, David L Conant, Ngoc Pham and 1 more

Abstract read
In one paragraph

Article in JAMA dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

David S LeeDepartment of Dermatology, Kaiser Permanente Northern California, Pleasanton.
Lusine GigoyanDivision of Research, Kaiser Permanente Northern California, Pleasanton.
Ryan E SellsDepartment of Dermatology, Kaiser Permanente Northern California, Pleasanton.
Joshua R NugentDivision of Research, Kaiser Permanente Northern California, Pleasanton.
Nelson B GoesKidney Transplant Clinics, Department of Nephrology, Kaiser Permanente Northern California, Pleasanton.
Hugh R HarrisDepartment of Pulmonary and Critical Care Medicine, Kaiser Permanente Northern California, Santa Clara.
Erna O NishimeCenter for Advanced Heart Failure Therapies, Cardiac Transplant Department, Kaiser Permanente Northern California, Santa Clara.
Gurpreet K RihalDepartment of Gastroenterology, Kaiser Permanente Northern California, San Jose.
David L ConantDepartment of Adult and Family Medicine, Kaiser Permanente Northern California, San Rafael.
Ngoc PhamDepartment of Dermatology, Kaiser Permanente Northern California, Santa Clara.
Marilyn L KwanDivision of Research, Kaiser Permanente Northern California, Pleasanton.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Solid organ transplant (SOT) recipients are at increased risk for skin cancer due to long-term immunosuppression. However, this risk is heterogeneous across the SOT population. The Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) incorporates established clinical risk factors to stratify SOT recipients into low-, medium-, high-, and very high-risk groups for posttransplant skin cancer. Objective: To assess skin cancer risk among SOT recipients and to evaluate the impact of a modified SUNTRAC-based surveillance program on screening rates, skin cancer incidence, and health care resource utilization. Design, Settings, and Participants: This was a retrospective cohort study of adult patients (≥18 years) who underwent SOT from January 1, 2016, to March 31, 2023. SOT recipients and nonrecipients were identified from the transplant registry of Kaiser Permanente Northern California (KPNC), an integrated health care delivery system providing care to more than 4.5 million members. SOT recipients were matched 1:20 on sex, race and ethnicity, and medical facility with nonrecipients. The study period was divided into preimplementation of the modified SUNTRAC (ie, KP-SUNTRAC) program (2016-2021) and postimplementation (2022-2024) periods. Included participants were followed up through March 31, 2024. Data were analyzed from July 2024 to June 2025. Exposure: Implementation of KP-SUNTRAC risk-based skin cancer surveillance program. Main Outcomes and Measures: Among SOT recipients, the number of skin cancer screenings; skin cancer incident rates for basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, or Merkel cell carcinoma; and health care resource utilization, measured by dermatology and nondermatology encounters and pathology specimen counts. Results: The analysis included 2083 SOT recipients matched with 26 199 nonrecipients and found a 7.8-fold increased risk of developing skin cancer posttransplant among the SOT recipients compared with nonrecipients (hazard ratio [HR], 7.78; 95% CI, 5.97-10.10). After KP-SUNTRAC implementation, the risk of first detected skin cancer was significantly higher in the postimplementation group (HR, 2.57; 95% CI, 1.76-3.73). During the postimplementation period, screening rates significantly improved among the high-risk (HR, 1.98; 95% CI, 1.39-2.82) and very high-risk (HR, 2.17; 95% CI, 1.21-3.86) groups compared with preimplementation. Health care utilization did not increase after KP-SUNTRAC implementation. Conclusions and Relevance: This cohort study found that KP-SUNTRAC was associated with improved skin cancer screening rates and detection among SOT recipients at higher risk of developing skin cancer, without increasing short-term health care utilization. This targeted surveillance approach supports timely diagnosis and has the potential to reduce morbidity and future health care costs.

Indexed as

Early Detection of CancerMelanomaOrgan TransplantationSkin NeoplasmsTransplant RecipientsAdultAgedBasal Cell CarcinomaCaliforniaCarcinoma, Squamous CellFemaleHumansIncidenceMaleMiddle AgedRegistries

Identifiers

PMID41091513
PMCPMC12529332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.